The new tools of microbiological diagnosis of tuberculosis;Les nouveaux outils de diagnostic microbiologique de la tuberculose maladie

Revue de Medecine Interne

Volumn 35, Issue 12, 2014, Pages 794-800

  Guillet Caruba, C ^a   Martinez, V ^a,b   Doucet Populaire, F ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b Universite Paris Sud   (France)

Author keywords

Laboratory diagnosis; Molecular techniques; Tuberculosis

Indexed keywords

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; DELAYED DIAGNOSIS; GENE AMPLIFICATION; IMMUNOAFFINITY CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROBIOLOGICAL EXAMINATION; MICROSCOPY; MOLECULAR DIAGNOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; SHORT SURVEY; TUBERCULOSIS; GENETICS; HUMAN; INTERFERON GAMMA RELEASE ASSAY; ISOLATION AND PURIFICATION; MASS SPECTROMETRY; NUCLEIC ACID AMPLIFICATION; REAL TIME POLYMERASE CHAIN REACTION;

BACTERIAL DNA; TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; DNA, BACTERIAL; HUMANS; IMMUNOCHROMATOGRAPHY; INTERFERON-GAMMA RELEASE TESTS; MASS SPECTROMETRY; MICROSCOPY; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; TUBERCULOSIS;

EID: 84912525189     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2014.05.001     Document Type: Short Survey

References (44)

1. Figoni J., Antoine D. Les cas de tuberculose déclarés en France en 2009. BEH 2011, 22:258-260.
2. Lawn S.D., Zumla A.I. Tuberculosis. Lancet 2011, 378:57-72.
3. Tattevin P. [What causes diagnosis delay in tuberculosis?]. Rev Prat 2012, 62:487-489.
4. Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux. France, Paris; 2012. Site internet: cnrmyctb.free.fr n.d.
5. Lawn S.D., Wood R. Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis 2011, 204(Suppl. 4):S1159-S1167.
6. Rylance J., Pai M., Lienhardt C., Garner P. Priorities for tuberculosis research: a systematic review. Lancet Infect Dis 2010, 10:886-892.
7. Small P.M., Pai M. Tuberculosis diagnosis--time for a game change. N Engl J Med 2010, 363:1070-1071.
8. Steingart K.R., Ng V., Henry M., Hopewell P.C., Ramsay A., Cunningham J., et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006, 6:664-674.
9. Parsons L.M., Somoskövi A., Gutierrez C., Lee E., Paramasivan C.N., Abimiku A., et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev 2011, 24:314-350.
10. Urbanczik R. Present position of microscopy and of culture in diagnostic mycobacteriology. Zentralblatt Für Bakteriol Mikrobiol Hyg Ser Med Microbiol Infect Dis Virol Parasitol 1985, 260:81-87.
11. Horne D.J., Royce S.E., Gooze L., Narita M., Hopewell P.C., Nahid P., et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis 2010, 10:387-394.
12. Recommandations nationales Prévention de la transmission croisée par voie respiratoire: air et gouttelettes. Hygienes 2013.
13. Fitzwater S.P., Caviedes L., Gilman R.H., Coronel J., LaChira D., Salazar C., et al. Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy. Clin Infect Dis Off Publ Infect Dis Soc Am 2010, 51:371-378.
14. Parrish N.M., Carroll K.C. Role of the clinical mycobacteriology laboratory in diagnosis and management of tuberculosis in low-prevalence settings. J Clin Microbiol 2011, 49:772-776.
15. Kumar V.G., Urs T.A., Ranganath R.R. MPT 64Antigen detection for Rapid confirmation of M.tuberculosis isolates. BMC Res Notes 2011, 4:79.
16. Lawn S.D., Kerkhoff A.D., Vogt M., Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 2012, 12:201-209.
17. Lotz A., Ferroni A., Beretti J.-L., Dauphin B., Carbonnelle E., Guet-Revillet H., et al. Rapid identification of mycobacterial whole cells in solid and liquid culture media by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2010, 48:4481-4486.
18. El Khéchine A., Couderc C., Flaudrops C., Raoult D., Drancourt M. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry identification of mycobacteria in routine clinical practice. PloS One 2011, 6:e24720.
19. Bouakaze C., Keyser C., Gonzalez A., Sougakoff W., Veziris N., Dabernat H., et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry-based single nucleotide polymorphism genotyping assay using iPLEX gold technology for identification of Mycobacterium tuberculosis complex species and lineages. J Clin Microbiol 2011, 49:3292-3299.
20. Parrish N., Carrol K. Importance of improved TB diagnostics in addressing the extensively drug-resistant TB crisis. Future Microbiol 2008, 3:405-413.
21. Lin S-YG, Desmond E., Bonato D., Gross W., Siddiqi S. Multicenter evaluation of Bactec MGIT 960system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex. J Clin Microbiol 2009, 47:3630-3634.
22. Espasa M., Salvadó M., Vicente E., Tudó G., Alcaide F., Coll P., et al. Evaluation of the VersaTREK system compared to the Bactec MGIT 960system for first-line drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2012, 50:488-491.
23. Chang K.C., Yew W.W., Zhang Y. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob Agents Chemother 2011, 55:4499-4505.
24. Shah N.S., Moodley P., Babaria P., Moodley S., Ramtahal M., Richardson J., et al. Rapid diagnosis of tuberculosis and multidrug resistance by the microscopic-observation drug-susceptibility assay. Am J Respir Crit Care Med 2011, 183:1427-1433.
25. Zhao L., Xia Q., Lin N., Liu B., Zhao X., Liu Z., et al. Evaluation of BACTEC MGIT 960system for the second-line drugs susceptibility testing of Mycobacterium tuberculosis in China. J Microbiol Methods 2012, 91:212-214.
26. Sharma M., Thibert L., Chedore P., Shandro C., Jamieson F., Tyrrell G., et al. Canadian multicenter laboratory study for standardized second-line antimicrobial susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2011, 49:4112-4116.
27. ® MYCOTB panel and the agar proportion method for the susceptibility testing of Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol 2012, 31:835-839.
28. Ling D.I., Zwerling A.A., Pai M. Rapid diagnosis of drug-resistant TB using line probe assays: from evidence to policy. Expert Rev Respir Med 2008, 2:583-588.
29. Brossier F., Veziris N., Jarlier V., Sougakoff W. Performance of MTBDR plus for detecting high/low levels of Mycobacterium tuberculosis resistance to isoniazid. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 2009, 13:260-265.
30. Crudu V., Stratan E., Romancenco E., Allerheiligen V., Hillemann A., Moraru N. First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances. J Clin Microbiol 2012, 50:1264-1269.
31. Ignatyeva O., Kontsevaya I., Kovalyov A., Balabanova Y., Nikolayevskyy V., Toit K., et al. Detection of resistance to second-line antituberculosis drugs by use of the genotype MTBDRsl assay: a multicenter evaluation and feasibility study. J Clin Microbiol 2012, 50:1593-1597.
32. Van Zyl-Smit R.N., Binder A., Meldau R., Mishra H., Semple P.L., Theron G., et al. Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden. PloS One 2011, 6:e28815.
33. Theron G., Peter J., Meldau R., Khalfey H., Gina P., Matinyena B., et al. Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid. Thorax 2013.
34. Helb D., Jones M., Story E., Boehme C., Wallace E., Ho K., et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010, 48:229-237.
35. ® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013, 1:CD009593.
36. Park J.S. Recent advances in tuberculosis and nontuberculous mycobacteria lung disease. Tuberc Respir Dis 2013, 74:251-255.
37. Van Deun A., Aung K.J., Bola V., Lebeke R., Hossain M.A., de Rijk W.B., et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013, 51:2633-2640.
38. Rigouts L., Gumusboga M., de Rijk W.B., Nduwamahoro E., Uwizeye C., de Jong B., et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol 2013, 51:2641-2645.
39. Green C., Huggett J.F., Talbot E., Mwaba P., Reither K., Zumla A.I. Rapid diagnosis of tuberculosis through the detection of mycobacterial DNA in urine by nucleic acid amplification methods. Lancet Infect Dis 2009, 9:505-511.
40. Diel R., Goletti D., Ferrara G., Bothamley G., Cirillo D., Kampmann B., et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011, 37:88-99.
41. Rangaka M.X., Wilkinson K.A., Glynn J.R., Ling D., Menzies D., Mwansa-Kambafwile J., et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:45-55.
42. Goletti D., Sester M. Screening for latent infection with Mycobacterium tuberculosis: a plea for targeted testing in low endemic regions. Expert Rev Mol Diagn 2012, 12:231-234.
43. Groupe de travail.Haut Conseil de la Santé publique Tuberculose et tests de détection de l'interféron gamma 2011.
44. Martinez V., Castilla-Lievre M.A., Guillet-Caruba C., Grenier G., Fior R., Desarnaud S., et al. (18)F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response. Int J Tuberc Lung Dis 2012, 16:1180-1185.